Compare GSK plc (GSK) vs Nuscale Power Corporation (SMR) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

SMR (NuScale Power) trades at $7.83, down 8.85% on the day and near its 52-week lows. The stock faces significant fundamental challenges with negative net income margins (-2,066.55% in 2026) and consecutive earnings misses, though analyst sentiment remains mixed with a $12.25 consensus price target suggesting 56% upside. Technical indicators show bearish momentum with the price testing key support at $7.

The outlook hinges on NuScale's ability to commercialize its SMR technology amid growing AI power demand. While first-mover advantage and government support provide long-term potential, near-term risks include persistent operating losses, delayed revenue generation, and high cash burn requiring continued financing.